An analysis of phase 3 clinical trials over the past 16 years shows greater disease activity in those with certain comorbidities.
A preliminary study evaluating the effect of comorbidities on multiple sclerosis (MS) outcomes in a single clinical trial identified associations of anxiety and dyslipidemia with MS disease activity (NEJM JW Neurol Aug 17 2020 and Neurology 2020; 95:e44). To further assess such associations, investigators analyzed 17 trials with a total of 16,794 participants for clinical outcomes and comorbidities including depression, anxiety, hypertension, hyperlipidemia, migraine, diabetes, chronic lung disease, autoimmune thyroid disease, and cerebrovascular disease.
Regarding evidence of disease activity (EDA), participants with ≥3 comorbidities had a significantly elevated risk (hazard ratio, 1.14 hazard) compared with those with no comorbidities; ris…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)